Ketamine: Further observations on use, users and consequences;Ketamina: Nuevas observaciones sobre su consumo, consumidores y efectos

Adicciones

Volumn 15, Issue SUPPL. 2, 2003, Pages 135-166

  Jansen, Karl L R ^a   Theron, Lynn ^a  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

Glutamate; Ketamine; Near death experience (NDE); NMDA (N methyl D aspartate); Phencyclidine (PCP); Psychedelic; Receptors; Schizophrenia

Indexed keywords

KETAMINE; PHENCYCLIDINE;

DRUG DEPENDENCE; DRUG EFFECT; DRUG TOLERANCE; FAMILY HISTORY; HISTORY; HUMAN; NEUROSCIENCE; REVIEW; SCHIZOPHRENIA;

EID: 0346458823     PISSN: 02144840     EISSN: None     Source Type: Journal    
DOI: 10.20882/adicciones.458     Document Type: Review

References (212)

1. Abajian JC, Page P, Morgan M. 1973. Effects of droperidol and nitrazepam on emergence reactions following ketamine anesthesia. Anesthesia and Analgesia; Current Researches; 52: 385-9.
2. Adler CM, Malhotra AK, Elma I, Goldberg T, Egan M, Pickar D, Breier A. 1999. Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. American Journal of Psychiatry; 156: 1646-1649.
3. Anand A, Charney DS, Oren DA, Berman RM, Hu XS, Cappiello A, Krystal JH. 2000. Attenuation of the neuropsychiatric effects of ketamine and lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Archives of General Psychiatry; 57: 270-276.
4. Antal M, Musci G, Faludi A. 1978. Ketamine anaesthesia & intraocular pressure. Annals Opthalmology; 10: 1281-1289.
5. Arvanov VL, Wang RY. 1998. M100907, a selective 5-HT2A receptor antagonist and a potential antipsychotic drug, facilitates N-methyl-D-aspartate-receptor mediated neuro-transmission in the rat medial prefrontal cortical neurons in vitro. Neuropsychopharmacology; 18: 197-209.
6. Auer RN, Coupland SG, Jason G W, Archer DP, Payne J, Belzberg AJ, Ohtaki M, Tranmer BI. 1996. Postischemic therapy with MK-801 (dizocilpine) in a primate model of transient focal brain ischaemia. Molecular and Chemical Neuropathology; 29: 193-210.
7. Australian Bureau of Criminal Intelligence 1995. Australian Illicit Drug Report 1994. Australian Bureau of Criminal Intelligence, Canberra.
8. Australian Bureau of Criminal Intelligence 2000. Australian Illicit Drug Report 1998-99. Australian Bureau of Criminal Intelligence, Canberra.
9. Ahmed SN, Petchkovsky L. 1980. Abuse of ketamine. British Journal of Psychiatry; 137: 303.
10. Beardsley PM, Balster RL. 1987. Behavioral dependence upon phencyclidine and ketamine in the rat. Journal of Pharmacology and Experimental Therapeutics; 242: 203-211.
11. Bell R, Eccleston C, Kalso E. 2003. Ketamine as an adjuvant to opioids for cancer pain (Cochrane Review). Cochrane Database Syst Rev 2003; (1): CD003351.
12. Benveniste H, Drejer J, Schouseboe A, Diemer H. 1984. Elevation of extracellular concentrations of glutamate & aspartate in rat hippocampus during cerebral ischaemia monitored by microdialysis. Journal Neurochemistry; 43: 1369-1374.
13. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH. 2000. Antidepressant effects of ketamine in depressed patients. Biological Psychiatry; 47: 351-4.
14. Borgbjerg FM, Svensson BA, Frigast C, Gordh T. 1994. Histopathology after repeated intrathecal injections of preservative-free ketamine in the rabbit: a light and electron microscopic examination. Anesthesia Analgesia; 79: 105-111.
15. Breitmeier D, Passie T, Mansouri F, Albrecht K, Kleemann WJ. 2002. Autoerotic accident associated with self-applied ketamine. Int J Legal Med; 116: 113-6.
16. Byer DE, Gould AB. 1981. Development of tolerance to ketamine in an infant undergoing repeated anaesthesia. Anaesthesiology; 54: 255-256.
17. Calderone L, Grimes P, Shalev M. 1986. Acute reversible cataract induced by xylazine and by ketamine-xylazine anesthesia in rats and mice. Experimental Eye Research; 42: 331-7.
18. Cloud J. 1997. "Is Your Kid on K?" Time Magazine, 20/10/1997, pp. 56-57 -USA and Pacific editions only (but posted on World Wide Web)
19. Connell PH. 1958. Amphetamine psychosis. Institute of Psychiatry Maudsley Monographs 5, O.U.P
20. Corbett D. 1990. Ketamine blocks the plasticity associated with prefrontal cortex self-stimulation. Pharmacology Biochemistry and Behaviour; 37: 685-688.
21. Cotman CW, Monaghan D, Ganong A. 1988. Excitatory amino acid neurotransmission: NMDA receptors and Hebb-type synaptic plasticity. Annual Review of Neuroscience; 11: 61-80.
22. Coyle JT. 1997. The nagging question of the function of N-acetylaspartylglutamate. Neurobiology of Disease; 4: 231-8.
23. Crysell A. 1998. Lost in the K-hole. Muzik 40, September 1998, 45-48. (contact: muzik@ipc.co.uk)
24. Cumming JF. 1976. The development of an acute tolerance to ketamine. Anesthesia and Analgesia; 55: 788-791.
25. Curran V, Morgan C. 2000. Cognitive, dissociative and psychogenic effects of ketamine in recreational users on the night of drug use and 3 days later. Addiction; 95: 575-590.
26. Curran VH, Monoghan L. 2001. In and out of the K-hole: a comparison of the acute and residual effects of ketamine in frequent and infrequent ketamine users. Addiction; 96: 749-760.
27. Currie MA, Currie AL. 1984. Ketamine: effect of literacy on emergence phenomena, Annals of the Royal College of Surgeons of England; 66: 424-425.
28. Darracott-Cankovic R, Jansen KLR, Dillon P, Copeland J, Dalgarno P, Chandler C. 2003. Schizotypy, cognitive deficits and psychiatric symptoms linked with chronic ketamine use (unpublished manuscript).
29. DEA. 1997. Ketamine Abuse Increasing.http://www. usdoj.gov/dea/program/diverson/divpub/substanc/ketamine.htm
30. Dershwitz M, Sreter FA, Ryan JF. 1989. Ketamine does not trigger malignant hyperthermia in susceptible swine. Anesthesia & Analgesia; 69: 501-503.
31. Dillon P, Copeland J, Jansen KLR. 2003. Patterns of use and harms associated with non-medical ketamine use. Alcohol and Drug Dependence; 69: 23-28.
32. Dixon JF, Los GV, Hokin LE. 1994. Lithium stimulates glutamate "release" and inositol 1,4,5-trisphosphate accumulation via activation of the N-methyl-D-aspartate receptor in monkey and mouse cerebral cortex slices. Proceedings of the National Academy of Sciences U S A; 91: 8358-8362.
33. Domino EF, Chodoff P, Corssen G. 1965. Pharmacologic effects of CI-581, a new dissociative anesthetic, in man. Clinical and Pharmacological Therapeutics; 6: 279-291.
34. Dotson JW, Ackerman DL, West LJ. 1995. Ketamine abuse. Journal of Drug Issues; 25: 751-757.
35. Dragunow M, Currie RW, Faull RLM, Robertson HA, Jansen KLR. 1989. Immediate early genes, kindling and longterm potentiation. Neuroscience and Biobehavioral Reviews; 13: 301-313.
36. Drejer J, Honore T. 1987 Phencyclidine analogues inhibit NMDA-stimulated [3H]GABA release from cultured cortex neurons. European Journal of Pharmacology; 143: 287-290.
37. Durieux ME, Nietgen GW. 1997. Synergistic inhibition of muscarinic signalling by ketamine stereoisomers and the preservative benzthonium chloride. Anesthesiology; 86: 1326-1333.
38. Dursun SM, Deakin JF. 2001. Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study. J Psychopharmacol; 15: 297-301.
39. Ebert B, Mikkelson S, Thorkildsen C, Borgbjerg FM. 1997. Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord. European Journal Pharmacology; 333: 99-104.
40. Elliot K. 1995. N-methyl-D-aspartate (NMDA) receptors, mu and kappa opioid tolerance and perspectives on new analgesic drug development. Neuropsychopharmacology; 13: 347-356.
41. Ellison G. 1995. The N-methyl-D-aspartate antagonists phencyclidine, ketamine and dizocilpine as both behavioral and anatomical models of the dementias. Brain Research Reviews; 20: 250-267.
42. Engelhardt W. 1997 Recovery and psychomimetic reactions following S- (+)-ketamine. Anesthetist; 46 (Suppl 1): S38-S42.
43. Engelhard K, Werner C, Eberspacher E, Bachl M, Blobner M, Hildt E, Hutzler P, Kochs E. 2003. The Effect of the alpha(2)-Agonist Dexmedetomidine and the N-Methyl-D-Aspartate Antagonist S(+)-Ketamine on the Expression of Apoptosis-Regulating Proteins After Incomplete Cerebral Ischemia and Reperfusion in Rats. Anesth Analg; 96: 524-31.
44. Erhardt S, Engberg G. 2002. Increased phasic activity of dopaminergic neurones in the rat ventral tegmental area following pharmacologically elevated levels of endogenous kynurenic acid. Acta Physiol Scand; 175: 45-53.
45. Farber NB, Foster J, Duhan NL, Olney JW. 1996. Olanzapine and fluperlapine mimic clozapine in preventing MK-801 neurotoxicity. Schizophrenia Research; 21: 33-37.
46. Farber NB, Hanslick J, Kirby C, McWilliams L, Olney JW. 1998. Serotonergic agents that activate 5HT2A receptors prevent NMDA antagonist neurotoxicity. Neuropsychopharmacology, 18: 57-62.
47. Farber NB. 1998. Personal communication.
48. FDA. 1979. Ketamine Abuse. FDA Drug Bulletin 9, 24.
49. Feldman Z, Gurevitch B, Artru A, Oppenheim A, Shohami E, Reichenthal E, Shapira Y. 1996. Effect of magnesium given 1 hour after head trauma on brain edema and neurological outcome. Journal of Neurosurgery; 85: 131-137.
50. Felser JM, Orban DJ. 1982. Dystonic reaction after ketamine abuse. Annals of Emergency Medicine; 11: 673-674.
51. Fine J, Finestone EC. 1973. Sensory disturbances following ketamine anaesthesia: recurrent hallucinations. Anesthesia and Analgesia (Cleveland.); 53: 428.
52. Ghoneim MM, Hinrichs JV, Mewaldt SP, Peterson RC. 1985. Ketamine: behavioral effects of subanaesthetic doses. Journal of Clinical Psychopharmacology; 5: 70-77.
53. Gill JR, Stajic M. 2000. Ketamine in non-hospital and hospital deaths in New York City. Journal of Forensic Science; 45: 655-8.
54. Gough N. 2003. Ketamine: China's other white powder. TimeAsia.com http://www.time.com/ time/asia/covers/1101020520/ketamine.html
55. Grant IS, Nimmo WS, Clements JA. 1981. Pharmacokinetics and analgesic effects of i.m. and oral ketamine. British Journal of Anaesthesia; 53: 805-809.
56. Green SM, Rothrock SG, Lynch EL, Ho M, Harris T, Hestdalen R, Hopkins GA, Garrett W, Westcott K. 1998. Intramuscular ketamine for pediatric sedation in the emergency department: safety profile in 1,022 cases. Annals of Emergency Medicine; 31: 688-697.
57. Greene R. 2001. Circuit analysis of NMDAR hypofunction in the hippocampus, in vitro, and psychosis of schizophrenia. Hippocampus; 11: 569-77.
58. Grinspoon L, Bakalar SB. 1979. Psychedelic Drugs Reconsidered. New York: Basic Books/Harper Colophon.
59. Grof S. 1988. The Adventure of Self-Discovery - Dimensions of Consciousness and New Perspectives in Psychotherapy and Inner Exploration. New York: State University of NewYork (SUNY) Press.
60. Gross SR, Barrett SP, Shestowsky JS, Pihl RO. 2002. Ecstasy and drug consumption patterns: a Canadian rave population study. Can J Psychiatry; 47: 546-51.
61. Hall CH, Cassidy J. 1992. Young drug users adopt 'bad trip' anaesthetic. The Independent, 2 April, page 5.
62. Hansen G, Jensen SB, Chandreash L, Hilden T. 1988. The psychotropic effect of ketamine. Journal of Psychoactive Drugs; 20: 419-425.
63. Hayashi H, Dikkes P, Soriano SG. 2002. Repeated administration of ketamine may lead to neuronal degeneration in the developing rat brain. Paediatr Anaesth; 12: 770-4
64. Hefez A, Lanyi G. 1972. Neuropsychiatric manifestations of ketamine hydrochloride. The Israel Annals of Psychiatry and Related Disciplines; 10: 180-187.
65. Hejja P, Galloon S. 1975. A consideration of ketamine dreams. Canadian Anaesthesia Society Journal; 22: 100-105.
66. Herman BH, Vocci F, Bridge P. 1995. The effects of NMDA receptor antagonists and nitric oxide synthase inhibitors on opioid tolerance and withdrawal. Medication development issues for opiate addiction. Neuropsychopharmacology; 13: 269-293.
67. Hiroi N, Brown J, Haile C, Ye H, Greenberg ME, Nestler EJ. 1997. FosB mutant mice: Loss of chronic cocaine induction of Fos-related proteins and heightened sensitivity to cocaine's psychomotor and rewarding effects. Proc Natl Acad Sci USA; 94: 10397-10402.
68. Hirota K, Okawa H, Appadu BL, Grandy DK, Devi LA, Lambert DG. 1999. Stereoselective interaction of ketamine with recombinant mu, kappa, and delta opioid receptors expressed in Chinese hamster ovary cells. Anesthesiology; 90: 174-82.
69. Hope BT. 1998. Cocaine and the ATP-1 Transcription Factor. In: The Neurochemistry of Drugs of Abuse (Ed. Ali SF), New York: Annals of the New York Academy of Sciences 844, 1-6.
70. Humphries Y, Melson M, Gore D. 1997. Superiority of oral ketamine as an analgesic and sedative for wound care procedures in the pediatric patient with burns. Journal of Burn Care Rehabilitation; 18: 34-36.
71. Hurt PH, Ritchie EC. 1994. A case of ketamine dependence. American Journal of Psychiatry; 151: 779.
72. Hustveit O, Maurset A, Oye I. 1995. Interaction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors. Pharmacology and Toxicology; 77: 355-359.
73. Irifune M, Shimzu T, Nomoto M. 1991. Ketamine-induced hyperlocomotion associated with alteration of pre-synaptic components of dopamine neurons in the nucleus accumbens of mice. Pharmacology Biochemistry and Behavior; 40: 399-407.
74. Irifune M. 1997. Effects of ketamine on dopamine metabolism during anesthesia in discrete brain regions in mice: comparison with the effects during the recovery and subanesthetic phases. Brain Research; 763: 281-4.
75. Ishihara H. 1997. Uneventful total intravenous anaesthesia with ketamine for schizophrenic surgical patients. European Journal of Anaesthesiology; 14: 47-51.
76. James W. 1902. [1958] The Varieties of Religous Experience. New York: New American Library.
77. Jansen KLR. 1989. Near-death experience and the NMDA receptor. British Medical Journal; 298: 1708-9.
78. Jansen KLR. 1990. Ketamine: Can chronic use impair memory? International Journal of Addiction; 25: 133-9.
79. Jansen KLR. 1993. Non-medical use of ketamine. British Medical Journal; 306: 601-602.
80. Jansen KLR. 1996a. Neuroscience, ketamine and the near-death experience: the role of glutamate and the NMDA receptor. In: L.J. Bailey. & J. Yates (Eds.) The Near-Death Experience: A Reader. New York: Routledge, pp265-282.
81. Jansen KLR. 1996b. Using ketamine to induce the near-death experience: mechanism of action and therapeutic potential. In: C. Ratsch & J. R. Baker (Eds.) Yearbook for Ethnomedicine and the Study of Consciousness (Jahrbuch furr Ethnomedizin und Bewubtseinsforschung) Issue 4, 1995; Berlin: VWB, pp55-81.
82. Jansen KLR. 1997a. The ketamine model of the near-death experience: a central role for the NMDA receptor. Journal of Near-Death Studies; 16: 5-27.
83. Jansen KLR. 1997b. The Brain Drain. The Face; 3: 166-170.
84. Jansen KLR. 2000. A review of the non-medical use of ketamine: use, users and consequences. J Psychoactive Drugs; 32: 419-433.
85. Jansen KLR. 2001a. Ketamine: Dreams and Realities. Sarasota, Florida: Multidisciplinary Association for Psychedelic Studies (ISBN 0-9660019-3-1) (this book can only be obtained from www.maps.org).
86. Jansen KLR. 2001b. Mental health problems associated with MDMA use. In: Ecstasy: The Complete Guide (Ed. JA Holland). New York: Inner Traditions, p87-110.
87. Jansen KLR, Darracot-Cancovic R. 2001. The non-medical use of ketamine, part two: A review of problem use and dependence. J Psychoactive Drugs; 33: 151-8.
88. 3H]kainic acid binding sites. Neuroscience; 32: 587-607.
89. Johnstone RE. 1973. A ketamine trip. Anesthesiology; 39:460.
90. Kamaya H, Krishna PR. 1987. Ketamine addiction. Anesthesiology; 67: 861-862.
91. Kapur S, Seeman P. 2002. NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia. Mol Psychiatry; 7: 837-44.
92. Khanna JM, Chau A, Shah G. 1997. Effect of NMDA antagonists on rapid tolerance to benzodiazepines. Brain Research Bulletin; 42: 99-103.
93. Khanna JM, Shah G, Chau A. 1997. Effect of NMDA antagonists on rapid tolerance to ethanol under two different testing paradigms. Pharmacology Biochemistry and Behavior; 57: 693-697.
94. Khanna JM. 1998. Effect of NMDA antagonists on development of rapid tolerance to various barbiturates. Alcohol; 15: 9-18.
95. Khorramzedeh E, Lofty AO. 1976. Personality predisposition and emergence phenomena with ketamine. Psychosomatics; 17: 94-95.
96. Klausen NO, Wiberg-Jorgensen F, Chraemmer-Jorgensen B. 1983. Psychotomimetic reactions after low-dose ketamine infusion. British Journal of Anaesthesia; 55: 297-301.
97. Koek W. 1989. The phencyclidine (PCP) analog TCP shares cocaine-like but not other characteristic behavioral effects with PCP, ketamine, and MK-801. Journal of Pharmacology and Experimental Therapeutics; 250: 1019-1027.
98. Krumholz W, Demel C, Jung S, Meuthen G, Knecht J, Hempelmann G. 1995. The effects of thiopentone, etomidate, ketamine and midazolam on several bactericidal functions of polymorphonuclear leucocytes in vitro. European Journal of Anaesthesiology; 12: 141-146.
99. Krupitsky EM, Grinenko AY. 1997. Ketamine psychedelic therapy (KPT): a review of the results of ten years of research. Journal of Psychoactive Drugs; 29: 165-183.
100. Krupitsky E, Burakov A, Romanova T, Dunaevsky I, Strassman R, Grinenko A. 2002. Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up. J Subst Abuse Treat; 23: 273-83.
101. Krupitsky EM, Burakov AM, Romanova TN, Grinenko NI, Grinenko AY, Fletcher J, Petrakis IL, Krystal JH. 2001. Attenuation of ketamine effects by nimodipine pretreatment in recovering ethanol dependent men: psychopharmacologic implications of the interaction of NMDA and L-type calcium channel antagonists. Neuropsychopharmacology; 25: 936-47.
102. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, Charney DS. 1994. Subanesthetic effects of the noncompetitive antagonist ketamine in humans. Archives of General Psychiatry; 51: 199-214.
103. Krystal JH, Karper LP, Bennett A, D'Souza DC, Abi-Dargham A, Morrissey K, Abi-Saab D, Bremner JD, Bowers MB Jr, Suckow RF, Stetson P, Heninger GR, Charney DS. 1998. Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans. Psychopharmacology (Berl); 135: 213-229.
104. Krystal JH, Petrakis IL, Webb E, Cooney NL, Karper LP, Namanworth S, Stetson P, Trevisan LA, Charney DS. 1998. Dose-related ethanol-like effects of the NMDA antagonist, ketamine, in recently detoxified alcoholics. Archives of General Psychiatry; 55: 354-360.
105. Kudoh A, Takahira Y, Katagai H, Takazawa T. 2002. Small-dose ketamine improves the postoperative state of depressed patients. Anesth Analg; 95: 114-8.
106. Kugler J, Doenicke A. 1994. Ketamine-anticonvulsive and proconvulsive actions. Anaesthesist; 43 (Suppl 2): S2-S7.
107. Kumar A, Bajaj A, Sarkar P, Grover VK. 1992. The effect of music on ketamine induced emergence phenomena. Anaesthesia; 47: 438-439.
108. Lahti AC, Koffel B, LaPorte D, Tamminga CA. 1995. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology; 13: 9-19.
109. Lahti AC, Warfel D, Michaelidis T, Weiler MA, Frey K, Tamminga CA. 2001. Long-term outcome of patients who receive ketamine during research. Biol Psychiatry; 49: 869-75.
110. Leary T, Sirius RU. 1997. Design for Dying. London: Thorsons/HarperCollins.
111. Licata M, Pierini G, Popoli G. 1994. A fatal ketamine poisoning. Journal of Forensic Science; 39: 1314-1320.
112. Lilly JC. 1978. The Scientist: A Novel Autobiography. New York. Bantam Books/J. B. Lippincott. (republished by Ronin).
113. Lindefors N, Barati S, O'Connor WT. 1997. Differential effects of single and repeated ketamine administration on dopamine, serotonin and GABA transmission in rat medial prefrontal cortex. Brain Research; 759: 205-212.
114. Lu Y, France CP, Woods JH. 1992. Tolerance to the cataleptic effect of the N-methyl-D-aspartate (NMDA) receptor antagonists in pigeons: cross-tolerance between PCP-like compounds and competitive NMDA antagonists. Journal of Pharmacology and Experimental Therapeutics; 263: 499-504.
115. MacLennan FM. 1982. Ketamine tolerance and hallucinations in children. Anesthesia; 37: 1214-1225.
116. Malhotra AK, Pinals DA, Adler CM, Elman I, Clifton A, Pickar D, Breier A. 1997. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology; 17: 141-150.
117. Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D, Breier A. 1996. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology; 14: 301-307.
118. Malhotra AK, Breier A, Goldman D, Picken L, Pickar D. 1998. The apolipoprotein E epsilon 4 allele is associated with blunting of ketamine-induced psychosis in schizophrenia. A preliminary report. Neuropsychopharmacology; 19: 445-8.
119. Malinovsky JM, Lepage JY, Cozian A, Mussini JM, Pinaudt M, Souron R. 1993. Is ketamine or its preservative responsible for neurotoxicity in the rabbit? Anesthesiology; 78: 109-115.
120. Malinovsky JM, Servin F, Cozian A, Lepage JY, Pinaud M. 1996. Ketamine and norketamine plasma concentrations after i.v., nasal and rectal administration in children. British Journal of Anaesthesia; 77: 203-7.
121. Maneta MP. 1976. Biodisposition of ketamine in the rat: self-induction of metabolism. Journal of Pharmacology and Experimental Therapeutics; 196: 536-564.
122. Manohar S, Maxwell D, Winters WD. 1972. Development of e.e.g. seizure activity during and after chronic ketamine administration in the rat. Neuropharmacology; 11: 819.
123. Marsden JM, Gossop M, Sewart D, Rolfe A, Farrell M. 2000. Psychiatric symptoms among clients seeking treatment for drug dependence. British Journal of Psychiatry; 176: 285-289.
124. McCarthy DA, Harrigan SE. 1976. Dependence producing capacity of ketamine in Macaca mulatta. Anaesthesiology; 399: 160-168.
125. Medoff DR, Holcomb HH, Lahti AC, Tamminga CA. 2001. Probing the human hippocampus using rCBF: contrasts in schizophrenia. Hippocampus; 11: 543-50.
126. Meliska CJ, Trevort AJ. 1978. Differential effects of ketamine on schedule-controlled responding and motility. Pharmacology Biochemistry and Behaiour; 8: 679-683.
127. Mills IH, Park GR, Manara AR, Merriman RJ. 1998. Treatment of compulsive behaviour in eating disorders with intermittent ketamine infusions. Quarterly Journal of Medicine; 91: 493-503.
128. Miranda AF, Boegman RJ, Beninger RJ, Jhamandas K. 1997. Protection against quinolinic acid-mediated excitotoxicity in nigrostriatal dopaminergic neurons by endogenous kynurenic acid. Neuroscience; 78: 967-975.
129. Modvig KM, Nielsen SF. 1977. Psychological changes in children after anaesthesia: a comparison between halothane and ketamine. Acta Anaesthesiology Scandinavica; 21: 541-544.
130. Moghaddam B, Adams B, Verma A, Daly D. 1997. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. Journal of Neuroscience; 7: 2921-2927.
131. Moore KA, Sklerov J, Levine B, Jacobs AJ. 2001. Urine concentrations of ketamine and norketamine following illegal consumption. J Anal Toxicol; 25: 583-8.
132. Moore M, Alltounian H. 1978. Journeys Into The BrightWorld. Massachusetts: Para Research.
133. Moore NN, Bostwick JM. 1999. Ketamine dependence in anesthesia providers. Psychosomatics; 40:356-359.
134. Moreton JE. 1977. Ketamine self-administration by the rhesus monkey. Journal of Pharmacology and Experimental Therapeutics; 203: 303-309.
135. Morita T, Hitomi S, Saito S, Fujita T, Uchihashi Y, Kuribara H. 1995. Repeated ketamine administration produces up-regulation of muscarinic acetylcholine receptors in the forebrain, and reduces behavioral sensitivity to scopolamine in mice. Psychopharmacology (Berl); 117: 396-402.
136. Nakao S, Adachi T, Murakawa M, Shinomura T, Kurata J, Shichino T, Shibata M, Tocyama I, Kimura H, Mori K. 1996. Halothane and diazepam inhibit ketamine-induced c-fos expression in the rat cingulate cortex. Anesthesiology; 85: 874-882.
137. Nakao S, Arai T, Mori K, Yasuhara O, Tooyama I, Kimura H. 1993. High-dose ketamine does not induce c-Fos protein expression in rat hippocampus. Neuroscience Letters; 151: 33-36.
138. Narimatsu E, Kawamata Y, Kawamata M, Fujimura N, Namiki A. 2002. NMDA receptor-mediated mechanism of ketamine-induced facilitation of glutamatergic excitatory synaptic transmission. Brain Res; 953: 272-5.
139. Narita M, Yoshizawa K, Nomura M, Aoki K, Suzuki T. 2001. Role of the NMDA receptor subunit in the expression of the discriminative stimulus effect induced by ketamine. Eur J Pharmacol; 423: 41-6.
140. Nishimura M, Sato K. 1999. Ketamine stereoselectively inhibits rat dopamine transporter. Neuroscience Letters; 274: 131-4.
141. Nishina K, Akamatsu H, Mikawa K, Shiga M, Maekawa N, Obara H, Niwa Y. 1998. The inhibitory effects of thiopental, midazolam, and ketamine on human neutrophil functions. Anesthesia and Analgesia; 86: 159-165.
142. Obiaya MO, Dakaraju P, Binitie AO. 1981. Ketamine emergence and personality. The East African Medical Journal; July 1981: 489-493.
143. Olney J. 1994. Neurotoxicity of NMDA receptor antagonists: an overview. Psychopharmacology Bulletin; 30: 533-540.
144. Olney J. 2002. New insights and new issues in developmental neurotoxicology. Neurotoxicology; 23: 659-68.
145. Olney JW, Labruyere J, Price MT. 1989. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science; 244: 1360-1362.
146. Olney JW, Labruyere J, Wang G, Wozniak DF, Price MT, Sesma MA. 1991. NMDA antagonist neurotoxicity: mechanism and prevention. Science, 254: 1515-1518.
147. Orser B, Smith D, Henderson S, Gelb A. 1997 Magnesium deficiency increases ketamine sensitivity in rats. Canadian Journal of Anaesthesia; 44: 883-890.
148. Oyama T, Matsumoto F, Kudo T. 1970. Effects of ketamine on adrenocortical function in man. Anesthesia and Analgesia; 49: 697-700.
149. Parke-Davis Product Information Sheet: Ketalar. 1999-2000. ABPI Compendium of Data Sheets and Summaries of Product Characteristics, 1999-2000. London: Datapharm Publications ltd, p 1120-22.
150. Perel A, Davidson JT. 1976. Recurrent hallucinations following ketamine. Anaesthesia; 31: 1081-1083.
151. Pfeiffer A, Brantl V, Herz A, Emrich HM. 1986. Psychotomimesis mediated by k opiate receptors. Science; 233: 774-6.
152. Plourde G, Baribeau J, Bonhomme V. 1997 Ketamine increases the amplitude of the 40-Hz auditory steady-state response in humans. British Journal of Anaesthesia; 78: 524-529.
153. Poole R, Brabbins C. 1996. Drug induced psychosis. British Journal of Psychiatry; 168: 135-138.
154. Reier CE. 1971. Ketamine-'dissociative agent' or hallucinogen? New England Journal of Medicine; 284: 791-2.
155. Release 1997. Release drugs and dance survey: an insight into the culture. (contact: Release, 388 Old Street, London EC1V 9LT, U.K.).
156. Rice SR, Niu N, Berman DB, Heston LL, Sobell JL. 2001. Identification of single nucleotide polymorphisms (SNPs) and other sequence changes and estimation of nucleotide diversity in coding and flanking regions of the NMDAR1 receptor gene in schizophrenic patients. Mol Psychiatry; 6: 274-84.
157. Richardson JD, Aanonsen L, Hargreaves KM. 1998. Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia. Journal of Neuroscience; 18: 451-457
158. Riley SC, James C, Gregory D, Dingle H, Cadger M. 2001. Patterns of recreational drug use at dance events in Edinburgh, Scotland. Addiction; 96: 1035-47
159. Rogo DS. 1984. Ketamine and the near-death experience. Anabiosis: The Journal of Near-Death Studies; 4: 87-96.
160. Rothman SM, Olney JW. 1987. Excitotoxicity & the NMDA receptor. Trends in Neurosciences; 10: 299-302.
161. Rozza A, Masoero E, Favalli L, Lanza E, Govoni S, RizzoV, Montalbetti L. 2000. Influence of different anaesthetics on extracellular aminoacids in rat brain. Journal of Neuroscience Methods; 101: 165-169.
162. Sabom MB. 1982. Recollections of Death: A Medical Investigation. New York: Harper and Row.
163. Sarramon C, Verdoux H, Schmidtt L, Bourgeoise M. 1999. Addiction and personality traits: sensation seeking, anhedonia, impulsivity. Encephale; 25: 569-75.
164. Sato M. 1992. A lasting vulnerability to psychosis in patients with previous metamphetamine psychosis. In: The Neurobiology of Drug and Alcohol Addiction (Ed.s Kalivas PH, Samson HH). Annals of the New York Academy of Sciences 654, 160-170.
165. Schorn TOF, Whitwam JG. 1980. Are there long term effects of ketamine on the nervous system? British Journal of Anesthesia; 52: 967-968.
166. Schwender D, Daunderer M, Kunze-Kronawitter H, Klasing S, Poppel E, Peter K. 1997. Awareness during general anaesthesia-incidence, clinical relevance and monitoring. Acta Anaesthesiology Scandinavica Suppl; 11: 313-314.
167. Sharp FR, Butman M, Aardalen K, Nickolenko J, Nakki R, Massa SM, Swanson RA, Sagar SM. 1994. Neuronal injury produced by NMDA antagonists can be detected using heat shock proteins and can be blocked with antipsychotics. Psychopharmacology Bulletin; 30: 555-560.
168. Sharp FR 1998. Personal communication.
169. Shi L, Fatemi SH, Sidwell RW, Patterson PH. 2003. Maternal influenza infection causes marked behavioral and pharmacological changes in the offspring. J Neurosci; 23: 297-302.
170. Shimoyama N. 1996. Ketamine attenuates and reverses morphine tolerance in rodents. Anesthesiology; 85: 1357-1366.
171. Siegel RK. 1978. Phencyclidine and ketamine intoxication: a study of recreational users. In: Phencyclidine Abuse: An Appraisal. (ed. R. C. Peterson and R. C. Stillman) pp119 - 140, National Institute on Drug Abuse Research Monograph 21. NIDA, Rockville, Maryland.
172. Sklar GS, Zukin SR, Reilley TA. 1981. Adverse reactions to ketamine anesthesia. Abolition by a psychological technique. Anaesthesia; 36: 183-190.
173. Skovmand K. 1996. Swedes alarmed at ketamine misuse. The Lancet; 348: 122.
174. Slaby A. 1994. Handbook of Psychiatric Emergencies, Fourth Edition. Connecticut: Appleton and Lange.
175. Smith DJ. 1980. The interaction of ketamine with the opiate receptor. Life Sciences; 26: 789-795.
176. Smith JA, Santer LJ. 1993. Respiratory arrest following intramuscular ketamine injection in a 4-year old child. Annals of Emergency Medicine; 22: 613-615.
177. Sobel RM, Morgan BW, Murphy M. 1999. Ketamine in the ED: medical politics versus patient care. American Journal of Emergency Medicine; 17: 722-5.
178. Soyka M, Krupitski G, Volki G. 1993. Phenomenology of ketamine induced psychosis. Sucht; 5: 327-331.
179. Sputz R. 1989. I never met a reality I didn't like: A report on 'Vitamin K'. High Times, October 1989, 64-82.
180. Stafford P. 1992. Psychedelics Encyclopaedia. 3rd Ed., Berkeley: Ronin Publishing.
181. Stella N, Schweitzer P, Piomelli D. 1997. A second endogenous cannabinoid that modulates long-term potentiation. Nature; 388: 773-778.
182. Strassman RJ. 1984. Adverse reactions to psychedelic drugs: a review of the literature. Journal of Nervous and Mental Disease; 172: 477-595.
183. Sybert JW, Kyff JV. 1983. Ketamine treatment of status epilepticus. Anesthesiology; 58: 203.
184. Taube HD. 1975. Phencyclidine and ketamine: comparison with the effect of cocaine on the noradrenergic neurons of the rat brain cortex. Naunyn-Schmeidebergs Archives of experimental Pathology and Pharmcology; 291: 47-54.
185. Taura P, Fuster J, Blasi A, Martinez-Ocon J, Anglada T, Beltran J, Balust J, Tercero J, Garcia-Valdecasas JC. 2003. Post operative pain relief after hepatic resection in cirrhotic patients: the efficacy of a single small dose of ketamine plus morphine epidurally. Anesth Analg; 96: 475-80.
186. Taylor PA, Towey RM. 1971. Depression of laryngeal reflexes during ketamine anesthesia. British Medical Journal; ii: 688-9.
187. Thompson GE. 1972. Ketamine-induced convulsions. Anesthesiology; 37: 662-663.
188. Thomson AM, West DC, Lodge D. 1985. An N-methylaspartate receptor-mediated synapse in rat cerebral cortex: a site of action of ketamine? Nature; 313: 479-481.
189. Tomlinson A. 1994. Ketamine. World Anaesthesia OnLine. Issue 4 (1994) Article 5. http://www. hda.ox.ac.uk/wfsa/html/u04/u04-01010.htm
190. Topp L, Hando J, Degenhardt L, Dillon P, Roche A, Solowij N. 1998. Ecstasy Use in Australia. Monograph No. 39. Sydney: National Drug and Alcohol Research Centre.
191. Tsai G, Coyle JT. 2002. Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol; 42: 165-79.
192. Turner DM. 1994. The Essential Guide to Psychedelics. California: Panther Press (out of print, but located at http://www.geocities.com/HotSprings/Spa/4558/
193. Tweed WA, Minick M, Mymin D. 1972. Circulatory responses to ketamine. Anesthesiology; 37: 613-619.
194. Uchihashi Y. 1993. The repeated administration of ketamine induces an enhancement of its stimulant action in mice. Japanese Journal of Pharmacology; 61: 149-151.
195. Uchihashi Y, Kuribara H. 1993. SCH 23390 equivalently, butYM-09151-2 differentially reduces the stimulant effects of methamphetamine, MK-801 and ketamine: assessment by discrete shuttle avoidance in mice. Japan Journal of Pharmacology; 62: 111-4.
196. Van der Kolk BA. 1997 The psychobiology of posttraumatic stress disorder. Journal of Clinical Psychiatry; 58 (Suppl. 9): 16-24.
197. Verma A, Moghaddam B. 1996. NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine, Journal of Neuroscience; 16: 373-379.
198. Vollenweider FX, Leenders K.L, Oye I, Hell D, Angst J. 1997a. Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). European Neuropsychopharmacology; 7: 25-38.
199. 18F)fluorodeoxyglucose (FDG). European Neuropsychopharmacology; 7: 9-24.
200. Weiner AL, Vieira L, McKay CA, Bayer MJ. 2000. Ketamine abusers presenting to the Emergency Department: A case series. Journal of Emergency Medicine; 18: 447-451.
201. Weiss J. 1986. Ketamine protects cultured neocortical neurons from hypoxic injury. Brain Research; 380: 186-190.
202. White MJ, Ryan C. 1996. Pharmacological properties of ketamine. Drug and Alcohol Review; 15: 145-155.
203. Williams K, Dichter MA, Molinoff PB. 1992. Upregulation of N-methyl-D-aspartate receptors on cultured cortical neurons after exposure to antagonists. Molecular Pharmacology; 42: 147-151.
204. Winters WD. 1988. Ketamine- and morphine-induced analgesia and catalepsy. I. Tolerance, Cross-Tolerance, Potentiation, residual morphine levels and naloxone action in the rat. Journal of Pharmacology and Experimental Therapeutics; 244: 51-57
205. World Health Organisation. 1992. The ICD-10 Classification of Mental and Behavioural Disorders. Geneva.146.
206. Yanagihara Y, Ohtani M, Kariya S, Uchino K, Hiraishi T, Ashizawa N, Aoyama T, Yamamura Y, Yamada Y, Iga T. 2003. Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers. Biopharm Drug Dispos; 24: 37-43.
207. Yang X. 1996. Evidence for a selective effect of ethanol on N-methyl-d-aspartate responses: ethanol affects a subtype of the ifenprodil-sensitive N-methyl-d-aspartate receptors. Journal of Pharmacology and Experimental Therapeutics; 278: 114-124.
208. Yilmaz A, Schulz D, Aksoy A, Canbeyli R. 2002. Prolonged effect of an anesthetic dose of ketamine on behavioral despair. Pharmacol Biochem Behav; 71: 341-4.
209. Zielmann S, Grote R. 1995. The effects of long-term sedation on intestinal function. Anaesthesist; 44 (Suppl 3): S549-S558.
210. Zsigmond EK. 1971. Malignant hyperthermia with subsequent uneventful anesthesia. Anesthesia and Analgesia; 50: 1111-2
211. Zsigmond EK. 1976. Arterial hypoxemia caused by i.v. ketamine. Anesthesia and Analgesia; 55: 311-314.
212. Zsigmond EK, Kelsch RC. 1974. Elevated plasma norepinephrine concentration during ketamine anesthesia. Clinical Pharmacology and Therapeutics; 14: 149.